One slight correction in case anyone uses it in as part of an investment calculation. Linkedin is owned by Microsoft, not Salesforce. They bought them back in 2016.CRM has always been on my radar since I use it at work and they own LinkedIn, but I haven't been able to get past their P/E ratio and lower than projected growth rates. I just know it will be a waste of time to run the DCF on them. It's probably better to look at P/S with a company like CRM, but the market is not especially kind to companies selling based on sales multiples of late.
Pharmaceuticals are tough. You can't just look at revenue and cash flows. You actually have to read some analysis or their 10K to get an idea of what drugs they have in the pipe as well as their current drugs that are coming off patent. That industry is not a core competency of mine so I have stayed away.
I think JNJ would be a smart play in theory provided valuation is good because of their pharmaceuticals business is paired with a solid consumer staples business to provide stability but even JNJ is spinning off their pharma business.
Last edited: